• Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery
  • Global ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataIntelo
  • Commercial rollout supported by Nora Pharma’s established Canadian distribution network, further expanding Sunshine Biopharma’s generic prescription drug portfolio

FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the “Company”), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the areas of oncology and antivirals, is pleased to announce that it has launched generic Ondansetron tablets of 4mg and 8mg in the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran®.

Ondansetron is widely prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that trigger nausea and vomiting. By offering two strengths (4mg and 8mg) and film-coated tablets, healthcare providers can better tailor the treatment to individual patient needs and physical condition.

According to DataIntelo, the global Ondansetron market was valued at $1.82 billion in 2025 and is projected to reach $2.98 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.6%. The rapid growth is driven by escalating cancer diagnoses worldwide, increased number of surgical procedures, and broad-based adoption of Ondansetron across multiple clinical indications. The global Nausea Medicine Market is growing steadily, fueled by increasing cases of nausea related to chemotherapy, motion sickness, gastrointestinal issues, and pregnancy. According to IQVIA Pharmafocus 2028, the Canadian pharmaceutical market accounts for approximately 2.1% of the global pharmaceutical market and ranks as the 6th largest worldwide.

Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Ondansetron to our portfolio of drugs represents a strategic expansion for the Company into the area of nausea and vomiting caused by cancer therapy.

“Launching Ondansetron oral tablets represents another decisive step in scaling Sunshine Biopharma’s generics business,” said Dr. Steve Slilaty, CEO. “This product enhances our competitive position and reflects our ongoing commitment to broadening access to dependable, much needed pharmaceuticals.”

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 61 generic prescription drugs on the market in Canada and approximately 11 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

All registered trademarks are the property of their respective owners.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

Media gallery

About The Author
Sunshine Biopharma Inc.